drugset / Trial / NCT00141102

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

NCT00141102

Phase 4 Completed 4484 enrolled Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.

Timeline

Start
2005-10
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Comparator Diclofenac Other / unclassified 75 mg
Comparator Omeprazole Other / unclassified 20 mg